-
R&D Status of Drugs Based on Influenza Pathogenesis (Part Two)
PharmaSources/Xiao Michong
March 16, 2022
Influenza virus RNA polymerase is a protein complex composed of PA, PB1 and PB2 subunits. PA has endonuclease activity and can induce proteolysis. PB1 has RNA polymerase activity...
-
A Better Anti-Influenza Solution: Roche’s Blockbuster New Drug Applied for Marketing in China
PharmaSources/Xiaoyaowan
June 24, 2020
According to the website of the CDE on June 10, the marketing applications of Roche for its new drug Baloxavir Marboxil Tablets in China have been accepted by the CDE.
-
First people dosed with a quadrivalent seasonal flu mRNA vaccine
europeanpharmaceuticalreview
July 09, 2021
The Phase I/II trial will assess the safety, reactogenicity and immunogenicity of Moderna’s mRNA-1010 seasonal flu vaccine.
-
Sanofi Invests $425M in Flu Vaccine Manufacturing Facility
contractpharma
June 18, 2021
Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.
-
First-in-human universal flu vaccine trial begins
europeanpharmaceuticalreview
June 03, 2021
The US National Institutes of Health have begun a first-in-human trial to assess the safety and immunogenicity of a potential universal influenza vaccine candidate, FluMos-v1.
-
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate
worldpharmanews
May 11, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate.
-
Cell-based seasonal influenza vaccine safe and effective in children
europeanpharmaceuticalreview
May 08, 2021
Phase III data shows Seqirus’ cell-based quadrivalent seasonal influenza vaccine was as effective and safe as an equivalent FDA-approved egg-based vaccine in paediatric patients.
-
Cidara Therapeutics signs deal with Janssen for antiviral conjugates to prevent, treat influenza
expresspharma
April 06, 2021
Cidara Therapeutics announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals to develop and commercialise Cidara’s Cloudbreak antiviral conjugates (AVCs) for the prevention and ...
-
FDA Warns of Potential False Results with Roche Molecular Systems for COVID, Flu Test
americanpharmaceuticalreview
March 22, 2021
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff, point-of-care (POC) facility staff, and health care providers that false positive results can occur with the Roche Molecular Systems, Inc. (Roche) cobas SARS-CoV-2 & ...
-
Vaccine development software shows promise in influenza effort, could help defeat coronavirus
worldpharmanews
March 04, 2021
A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.